Ubrogepant Shows Enhanced Efficacy When Given During Mild Migraine Pain Phase
New data shows the first oral CGRP antagonist ubrogepant demonstrates better efficacy when administered during mild pain rather than waiting for moderate-to-severe migraine pain.